

UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT PUBLIC ADVISORY COMMITTEE MEETING

Alexandria, Virginia

Thursday, November 30, 2023

1 PARTICIPANTS:

2 Patent Public Advisory Committee (PPAC) Members:

3 SUZANNE HARRISON, Chair

4 HEIDI NEBEL, Vice Chair

5 STEVEN CALTRIDER

6 DANIEL BROWN

7 CHARLES DUAN

8 OLIVIA TSAI

9 LOLETTA DARDEN

10 HENRY HADAD

11 JUDGE SUSAN BRADEN (Ret.)

12 USPTO:

13 KATHI VIDAL
14 Under Secretary of Commerce for
15 Intellectual Property and Director of
16 United States Patent and Trademark
17 Office

18 DERRICK BRENT
19 Deputy Director of the USPTO and.
20 Deputy Undersecretary of Commerce for.
21 Intellectual Property

22 JAMIE HOLCOMBE
CIO

BRIAN HANLON
Acting Deputy Commissioner for Patents

VAISHALI UDUPA
Commissioner for Patents

1 PARTICIPANTS (CONT'D):

2 ROBIN EVANS
Deputy Commissioner for Patents

3
4 GREG VIDOVICH
Assistant Commissioner for Patents

5 DAN RYMAN
Acting Deputy Commissioner for Patents

6
7 REMY YUCEL
Patents

8 Union Representatives:

9 KATHLEEN DUDA

10 CATHERINE FAINT

11 VERNON AKO TOWLER

12

13 * * * * *

14

15

16

17

18

19

20

21

22

1 P R O C E E D I N G S

2 (10:07 a.m.)

3 MS. HARRISON: Hello everybody. My name
4 is Suzanne Harrison, and I'm the current Chair of
5 PPAC, and I'd like to welcome you to our second
6 public meeting this year. We are here to discuss
7 the Annual Report and answer any questions you may
8 have.

9 Before we start, we're going to do a
10 round of introductions, first on the PPAC side and
11 then on the USPTO side. And for the USPTO folks,
12 if you can also introduce the folks who are online
13 as well, that would be helpful. We're really
14 excited about this meeting and to show you all the
15 hard work we've been doing with Director Vidal and
16 Deputy Director Brent and the rest of the USPTO
17 staff. We're very proud of all of the work that
18 has been accomplished this year, and so we're
19 happy to share that with you.

20 As I said before, my name is Suzanne
21 Harrison, I'm in my second year of PPAC. My Vice
22 Chair is Heidi.

1 MS. NEBEL: Heidi Nebel, this is my
2 second year in PPAC, I'm the current Vice Chair,
3 and I'm an attorney in private practice.

4 MR. CALTRIDER: I'm Steve Caltrider, I'm
5 Vice President and Chief IP Counsel at the
6 Dana-Farber Cancer Institute. I'm in my last year
7 of PPAC. In fact this is my last meeting of PPAC,
8 and I've received my notice I need to turn my
9 badge in today. So it's kind of intimidating,
10 it's almost, we said we weren't going to get
11 tearful and I'm almost getting a little bit
12 tearful because when you get the notice saying
13 turn your badge in, it kind of, it really hits.
14 I've had a terrific run, it's been a great
15 pleasure to work with the office and the staff,
16 and I look forward to at least my last meeting,
17 and hopefully I can contribute in some way going
18 forward. Thank you.

19 MS. DARDEN: Good morning everyone, my
20 name is Loletta Darden, I am in my first year of
21 PPAC. I am a Professor at George Washington
22 University Law School, and I'm also in private

1 practice.

2 MR. DUAN: Hi there, I'm Charles Duan,
3 this is my second year on PPAC, and I am also a
4 Professor of Law at the American University of
5 Washington College of Law.

6 MS. TSAI: Good morning everyone, I'm
7 Olivia Tsai, I'm head of IP at Cruise Self-Driving
8 Car Company, and this is my first year on PPAC.

9 MR. HADAD: Good morning, my name is
10 Henry Hadad. I am completing my first year on
11 PPAC, and I am also the Chief Intellectual
12 Property Counsel at Bristol-Myers Squibb.

13 MS. HARRISON: Dan, can you introduce
14 yourself, please. We can't hear you. So this is
15 Dan Brown, is a Professor at Northwestern and also
16 is the Independent Inventor Rep. And he is in his
17 third year and final year of PPAC.

18 MS. VIDAL: I'm Kathi Vidal, the
19 Director of the USPTO and the Under Secretary of
20 Commerce for Intellectual Property. I'm just so
21 excited to be here with everyone today and to talk
22 to you about the great work that PPAC has done

1 over the last year. Derrick.

2 MR. BRENT: Derrick Brent, Deputy
3 Director of the USPTO and Deputy Under Secretary
4 of Commerce for Intellectual Property. Vaishali.

5 MS. UDUPA: Hello everyone, I'm Vaishali
6 Udupa, I'm Commissioner for Patents, and you can
7 probably hear from my voice I'm a little under the
8 weather, so I'm making sure no one gets sick in
9 person. But I'm very excited to be here. Thank
10 you.

11 MS. EVANS: Good morning, I'm Robin
12 Evans, Deputy Commissioner for Patents. And like
13 everyone else said, glad to be here today.

14 MS. YUCEL: Hello, Remy Yucel from
15 Patents. Thank you.

16 MR. RYMAN: Dan Ryman, Acting Deputy
17 Commissioner for Patents.

18 MR. HANLON: Brian Hanlon, Acting Deputy
19 Commissioner for Patents.

20 MR. VIDOVICH: Greg Vidovich, Assistant
21 Commissioner for Patents. I'm here for Rick Seidel
22 who is the Deputy for Patents.

1 MR. HOLCOME: I'm Jamie Holcombe, the
2 CIO.

3 MS. BONILLA: I'm Jackie Bonilla, I'm at
4 PPAC on detail as a Senior Legal Advisor to
5 Director Vidal.

6 MR. TIERNEY: Michael Tierney, Acting
7 Deputy Chief, PTAB.

8 MS. HARRISON: Is there anybody else
9 online from the Patent Office that would like to
10 introduce themselves? Okay. Cathy Faint, could
11 you introduce yourself, please.

12 Before we actually dive into the Annual
13 Report, Director Vidal would like to make some
14 remarks and share some thoughts with you, so I
15 will turn it over to her.

16 MS. VIDAL: Thank you. Again, real
17 excited to be here today, and I want to thank the
18 PPAC members for all the work that they've done
19 over the past year. We had an Executive Session
20 yesterday and I just wanted to acknowledge that
21 during my tenure we've expanded the role of the
22 PPAC, and by doing that we've had to experiment a

1 little bit with what the PPAC looks like and how
2 they're leaning in on various measures, and I
3 couldn't be more thrilled with the work we've done
4 over the last couple years. The group has been
5 extremely active. Every time you see something
6 from me they've reviewed it, they provided their
7 input, we've adjusted it based on their input, and
8 in addition to providing all that direct advice to
9 me and to the members of the USPTO, they've also
10 thought hard about how the PPAC can lean in and
11 better support the mission and vision of the
12 USPTO. So I want to thank each of them
13 individually and as a group for all the great work
14 on that.

15 I also want to thank Jennifer Lo for her
16 dedication to the PPAC. She keeps everything
17 running and makes sure that everything gets done,
18 such an incredible job, especially as we've
19 expanded the role and the PPAC has been extremely
20 active. So thank you, Jennifer.

21 And then of course I want to thank all
22 of my colleagues that, you know, as we've expanded

1 the role in the PPAC we've also expanded our role
2 in terms of being more proactive, leaning in more
3 heavily to advance our mission and vision which we
4 all put together as a team. So their hard work,
5 their dedication, they're just excellent skilled
6 colleagues and I'm so delighted to work with each
7 one of them and want to thank them all personally.
8 Wish I could do that every day, try to.

9 Before I provide some opening remarks I
10 want to honor the three members who are departing
11 the PPAC. And it is, as I mentioned yesterday,
12 I'm excited for our next year, I look at these
13 journeys as year-by-year journeys where, you know,
14 in the first year we define as the year of
15 listening, and the second year we define the year
16 as year of impact, of making change. And this
17 next year we're now working all together to figure
18 out how we're going to define it. But as I'm
19 excited for the future and for the new people who
20 will be coming on board that we'll announce next
21 week, and for the new leadership, it's also a
22 little bit sad to see people departing who have

1 been such close colleagues in our mission and
2 vision.

3 With that I do want to acknowledge them
4 right now. I know that Dan Brown is online, I
5 will start with him, and then mention Judge Susan
6 Braden as well, and then Steve Caltrider, who has
7 served as the lead of the PPAC. I want to make
8 sure that I acknowledge you and present you with a
9 few things.

10 So in terms of Judge Susan Braden, she
11 was here yesterday, I don't believe she's able to
12 be with us today. She's going to receive a
13 certificate for her service. I'm grateful for the
14 role that she has played, she brought a unique
15 perspective to the PPAC given her background. And
16 like all the members of the PPAC, she's involved
17 in trying to advance a strong innovation economy,
18 a strong IP economy, not just through her work on
19 the PPAC, but through her work outside of the
20 PPAC. So I'm grateful for all of her efforts, and
21 she will be receiving a certificate for that.

22 As with all three departing members, I

1 have invited them to continue to dialogue with me
2 on things that they're seeing that they believe we
3 can do better, areas they think we should lean in
4 on, just as I would invite all of you to do so as
5 well.

6 Dan Brown is online, and he has been
7 extremely active during his tenure representing
8 the individual inventor, which is a very important
9 voice. We're not going to lose the voice of the
10 independent inventor as we move forward, at the
11 same time we particularly also do not want to lose
12 Dan Brown's voice. So he's going to continue to
13 work on some of the work that we're doing to think
14 about how we solve for things keeping the
15 individual inventor in mind. So I really look
16 forward to the work that we'll do together, and
17 also want to thank him for leaning in heavily on
18 that area and just advising generally on
19 everything that we're doing from the perspective
20 of the individual inventor. So, Dan, I'm sorry
21 that you're not here in person, I know that you
22 come here often in person to advance the work that

1 we've done, really appreciate that, and we'll be
2 sending a certificate to you as well.

3 Steve is here in person so he can give
4 his badge back. Steve is here in person, and he
5 gets to be presented with both a certificate and
6 the USPTO flag that flew over the USPTO since he
7 did serve as the PPAC Chair. I want to thank him
8 for, you know, all the great work that he's done.
9 You know, Steve has represented not only his
10 industry, the pharmaceutical industry, but has
11 brought a perspective that's been very balanced.
12 He's played a very balanced role in terms of
13 leading the PPAC, in terms of making sure
14 everybody's voices are heard, not only his own, in
15 particular also with Dan Brown to make sure the
16 individual inventor's voice is heard in everything
17 that we're doing. So I thank him for his tenure,
18 he's been a trusted advisor and a good friend, so
19 really appreciate everything you've done.

20 And again, this is not the end, this is
21 just a transition, you continue your work without
22 a badge or pay. So I appreciate you signing up

1 for that. So with that I would like to present
2 you with both the certificate and the flag.
3 Here's the Certificate of Appreciation, and here's
4 the U.S. Flag.

5 I also want to take a minute to thank
6 our outgoing leadership. They have been extremely
7 active in the last year and have really worked to
8 rethink the PPAC's role as we've done the last two
9 years to make sure that PPAC is more active in the
10 work that we do and to think about how we advance
11 the PPAC in a way and the USPTO's work in a way
12 that helps our economy and that helps national
13 security, which are two things that are top of
14 mind when it comes to intellectual property
15 protection.

16 The outgoing PPAC Chairs, Suzanne
17 Harrison, thank you for your leadership. Thank
18 you for leaning in in those incredible ways. And
19 the outgoing Vice Chair, Heidi Nebel, I want to
20 thank you both for rethinking things, for
21 rethinking and aligning the work that you do with
22 the work that the USPTO does, which is not just on

1 topic, but on project-by-project basis, which I
2 think that vision of aligning the way we've
3 aligned, which is on the project-by-project basis,
4 has been very productive.

5 I do want to announce and congratulate
6 the new PPAC Chair and the new PPAC Vice Chair who
7 are going to, as we did when I came into the
8 Agency, take a fresh look at everything, and the
9 same thing that Heidi and Suzanne did, while
10 keeping in mind that a lot of the stuff that we do
11 is great and we want to double down on it, but
12 there's also a fresh view that we can do better,
13 every year we can do better.

14 So I want to introduce the new PPAC
15 Chair, Lolita Darden. So congratulations you two.
16 And the new PPAC Vice Chair, Charles Duan. Thank
17 you.

18 I also want to thank the PPAC members
19 again for everything they worked on over the past
20 year. It's been a lot of work, including the fact
21 that we are doing. I know that put an extra
22 burden on the group. But hearing your voices on

1 how we set these was extremely instructive because
2 it's a very complicated process. We needed to
3 make sure that we're doing the right thing, that
4 we get it right, that we provide the right
5 incentive for the behavior that we want to see,
6 but that we still make the whole enterprise
7 accessible to those who are small and medium-sized
8 enterprises and to the individual inventors. So
9 thank you for that, thank you for the 2023 Annual
10 Report, and for increasing awareness of the
11 importance of intellectual property, both as
12 members of the PPAC and in your individual
13 capacities. It's critical that our nation
14 continue to recognize the importance of
15 intellectual property, that we realize that it
16 drives our economy, that it creates solutions for
17 things like COVID, and that it's critical to
18 everything we do, including GDP and national
19 prosperity. So thank you for all of that.

20 I do want to reflect a little bit on the
21 past year. And I know that we have leaned in very
22 heavily when it comes to inclusive innovations. I

1 think the work that the team has done has been
2 remarkable. I will share just a couple stories.

3 So there was a woman that I first met in
4 Phoenix, and this woman, Ruth Elawaza, drove from
5 San Diego to Phoenix to attend one of our women
6 entrepreneurship events. And she wanted to show
7 us the three patents that she received. Ruth
8 initially had been put out of her job, she got
9 into an accident and couldn't work. She ended up
10 working cleaning hotels. And during that process
11 she realized that there could be a better system
12 for cleaning hotels, there's a better bedding
13 system so that sheets could be changed more
14 quickly. And luckily Ruth came upon the USPTO.
15 She came to some of our innovation events. And
16 through that process she learned the value of
17 intellectual property. And so she patented her
18 bedding system and actually received three patents
19 in total on her bedding system.

20 So she believed so strongly in how the
21 IP system had helped her, had lifted her out of
22 somebody who was working cleaning hotels into an

1 entrepreneur. And so she was excited about that
2 that she wanted to come meet me and bring her
3 three patents to show me.

4 Along the way she actually got a flat
5 tire, and she was not deterred. As most
6 entrepreneurs, she was not deterred. She stopped
7 in a couple towns to get the tire replaced and was
8 unable to find somebody to do it quickly. So she
9 proceeded to drive the rest of the way between San
10 Diego and Phoenix on a flat tire to get to the WE
11 event to see me. And told me her story and took a
12 picture with me and her three patents.

13 Her story just embodies the type of
14 people that we want to not only help find us, but
15 we want to go out and seek and find them and bring
16 them into the IP ecosystem, to lift them and their
17 communities out of their circumstances to make
18 sure that they all equally contribute in the fruit
19 of what is America.

20 I will also say that as I meet people
21 across the globe, even our youth, what I find is
22 that people are innovating in areas that matter to

1 them, and they're innovating in areas that are
2 emphatic. So for example, I was in Ronda, Spain
3 on a base there, a joint base with the U.S.
4 Military and the Spanish military. And there were
5 kids who were innovating before I got there in
6 anticipation for my arrival. And three of the
7 kids had invented something called a Pocket
8 Therapist.

9 So they had recognized that in our
10 schools there's a lot of issues around mental
11 health and that people struggle. And so they
12 invented a Pocket Therapist where the Pocket
13 Therapist looked basically like an iPhone but
14 would have buttons on it. So you could push a
15 button if you were feeling sad. And it would say,
16 did you think about talking to your friend,
17 Derrick Brent. Or give you other suggestions on
18 what you might want to do to lift yourself out of
19 different moods.

20 When I was in Hawaii this year on a
21 military base, when we were there for IP5, the
22 kids, each of the kids had to create an invention

1 and then they had a board where everybody posted
2 their invention by subject matter. And one of the
3 boards was climate. And there were so many posted
4 things on climate, you couldn't barely see
5 postings on the other subject matters.

6 These kids were inventing things like,
7 and these are 9, 10-year-old kids. Inventing
8 ideas like gloves where you could swim through the
9 oceans and the gloves would absorb plastic
10 particulates.

11 So just thinking about everybody that
12 we've met across the globe, including across
13 America, the work that we do on inclusive
14 innovation is critical. It's work we do with the
15 PPAC. We are working on a national inclusive
16 strategy, and the PPAC will be reviewing that,
17 giving us their insights on that, and we look
18 forward to continuing to advance that work.

19 So with all that work I know that that
20 gets a lot of attention and it's very exciting,
21 but there is a lot of work that we're doing on the
22 substance. Every day we're working on the

1 substance to make the system better for you.

2 I will say that this year we did
3 celebrate our 1 millionth design patent. It was a
4 very exciting celebration. It was given to
5 Augustina Huckabee from Fort Worth, Texas for a
6 dispensing cone. And, you know, as part of that
7 we honor the great work, not to all of our patent
8 examiners, but our design patent examiners as
9 well.

10 When I came on board I did mention that
11 I felt like design patent protection was a
12 protection that deserved equal attention to the
13 utility patents and other forms of IP protection.
14 And we've acted on that as a team. We've elevated
15 design patents within the USPTO. That is
16 something that was a reorganization that we sent
17 through Congress, so very excited about that.

18 We recently issued guidance, we are
19 doing work in the courts, and we brought on a
20 Marian Crock scholar to actually help us with our
21 work, including with training. So we recognize
22 the importance of design patent protection. We

1 are receiving more than 50,000 new design patent
2 applications every year, which is the most ever.
3 It took us 181 years to reach 1 million design
4 patents, at the rate of 35,000 new grants per
5 year, it will only take us 28 years to add another
6 1 million. So much work being done in the design
7 patent space.

8 Beyond that we are working to address
9 patent tendency and timeliness targets. We
10 identified the need to do that and we've made
11 great improvements. I just want to share a few.
12 So we implemented something called Catch up
13 Overtime. We changed the production unit being
14 output by our patents group by 750 production
15 units. We changed our examiner game sharing
16 award. That added about 4,700 additional
17 production units. It was the first improvement in
18 pre-examiner productivity since 2019, and it is
19 the largest improvement since 2015. We've updated
20 docketing programs to examine cases in proper
21 first-in, first-out date order. This resulted in
22 over 3,000 first actions per month being properly

1 redirected to our oldest cases.

2 We are going to continue that work while
3 continuing to focus on the robustness and
4 reliability of patent rights. We did ask you, the
5 public, for your feedback on robust and reliable
6 patents, thank you for that feedback and all the
7 feedback you've given us. We are also focused on
8 the clarity of the record. We've worked with the
9 PPAC over the last few weeks on some very quick
10 turnarounds so that we can advance those measures.
11 I want to thank them for the work on that. We are
12 constantly working on the robustness and
13 reliability, whether it's introducing new AI
14 searching, whether it's providing the right
15 training to our patent examiners, whether it's the
16 new work that we did over the course of the last
17 two years allowing examiners to be able to
18 collaborate to make sure that if a patent
19 application involved multiple technologies that
20 they could get the resources that they needed.

21 We also retired the EFS Web and Private
22 Pair. We retired that on November 15th in favor

1 of Patent Center. That is part of a long-term
2 effort led by Jamie and by the patent group to
3 update all of our technology. Before Jamie came
4 on board we would have technology go down for long
5 periods of time, it was antiquated. I heard a
6 story yesterday that we'd have to sometimes search
7 on eBay for technology to like replace parts of
8 our technology because it was so antiquated, it
9 was unbelievable. We know change is hard, we know
10 that as we improve you will find things that we
11 can improve on in terms of the technology.

12 We are not done listening, we listen a
13 lot before we made the final move. It was after
14 many years of Patent Center being in place, we're
15 still listening. If you see individual instances,
16 feel free to send them to me directly, somebody
17 did this week. I will forward it along. You can
18 send it to Vaishali, you can send it to Jamie or
19 anyone, because we want to make sure we're
20 continuing to improve the new technology. It's
21 far and above better than what we had before, but
22 that doesn't mean that we can't make it much more

1 user friendly, which we're aiming to do.

2 In terms of other USPTO programs, I will
3 say that in terms of expanding innovation, there's
4 a lot that we rolled out. We rolled out a
5 first-time filer program where those who are new
6 to the IP ecosystem can receive their patent more
7 quickly if they're under resourced. We are
8 working on having ambassadors throughout the
9 country, we are working on expanding the number of
10 patent and trademark resource centers so that you
11 can find us in your local library.

12 I wrote a letter recently to 600
13 libraries across the country, Virginia Tech
14 immediately signed up, we just found out recently
15 that one of our patent examiners went into his
16 library in HBC and they decided to sign up as
17 well. So we're onboarding at a very fast clip to
18 make sure we're providing the right resources.
19 And we're rethinking what PTRCs can do to make
20 sure that when you step into your library you know
21 immediately some of the services that they have to
22 offer.

1 We are educating our youth. Last year
2 we educated approximately 350,000 children across
3 the United States. We want to expand that as
4 well. It's important that we look at the IP and
5 innovation ecosystem from bottom up to make sure
6 that we're growing the work, that we're creating
7 in America that understands the value of IP from
8 the beginning, that understands that they can
9 benefit, and the country can benefit and the world
10 can benefit from all of their ideas and there is
11 the mechanism to making that happen.

12 Just recently we introduced a new
13 semiconductor technology, actually not just
14 recently. It's going to be introduced this week,
15 so very excited about that. The Semiconductor
16 Technology Expedited Review Pilot Program. So we
17 are aligning our work across government and across
18 the needs of the country, including when it comes
19 to advanced technology, emerging technology, and
20 supply chains. And so this is part of the work
21 that we're doing with CHIPS on supply chains.

22 We're in the last phase of our study on

1 the pro bono program, which as I mentioned so many
2 times, we double down on immediately when I came
3 on board, we increased the funding, we're
4 increasing the role of the pro bono, and we've had
5 remarkable results. And I know I've quoted this
6 often, but where it is right now the percent of
7 women on U.S. patents is between 12 and 13
8 percent. When we get out there and reach people
9 where they are it jumps to 43 percent women that
10 benefit from the program. 35 percent of those who
11 benefit from the program identify as
12 African-American or Black. And I could go down
13 the line, but the data just shows that there's
14 innovation everywhere, and while we are working
15 really hard to improve the system, including when
16 it comes to the PTAB, which I'll mention in a
17 second, it's really important that we bring more
18 people in as we improve things.

19 So also want to thank the PTAB and the
20 work everybody's done to think about everything
21 that PTAB does to work on the ANPRM and move that
22 to the ANPRM and move forward with what we

1 believe, based on your feedback, we should move
2 forward with. The PTAB is an incredible group of
3 dedicated judges and others who are really focused
4 on, you know, obviously rendering decisions that
5 they believe are fair based on the evidence. But
6 beyond that, so we can advance policy to tweak the
7 role of the PTAB to ensure that it best serves the
8 country. We are working hard to do that in many
9 vectors, as you're seen, and to be more
10 transparent and open and to make sure that the
11 system has the integrity it deserves based on
12 those who are in the PTAB. We've done a number of
13 measures, including on director review related to
14 that, etcetera. So just real excited about that
15 work.

16 So I will pause there. There's a lot
17 that we've done in the last year, all of it, all
18 of it on the patent side was with the help of
19 PPAC. They're indispensable to everything that we
20 do. It's important that we hear your voices, it
21 was all done with your voices as well. They've
22 looked at your voices. When we try and solve for

1 things they will also need your comments and help
2 advise me, they are the group that is my trusted
3 advisors. By statute I've taken maybe full, maybe
4 a lot of advantage of that, but just really
5 appreciate all that they've done.

6 And then other than that I would just
7 encourage you to spread the word on everything
8 that we're doing to make sure you're playing a
9 role in your communities advancing all the things
10 that we're advancing. You can play a role when it
11 comes to anything that we're doing, amplifying the
12 work with the Patent and Trademark Resource
13 Center, it's amplifying pro bono, getting
14 innovation education into the schools, getting the
15 word out on the importance of intellectual
16 property. So really appreciate this.

17 I'm going to watch the rest of this from
18 my office, I don't want to miss anything. But
19 just want to say thank you again to everybody
20 who's listening in and everybody sitting around
21 the table and in the other row today. Thank you.

22 MS. HARRISON: Thank you, Kathi. We at

1 PPAC have been really honored to have worked with
2 you so incredibly closely. And as she said
3 before, this is the year of impact. So we're
4 going to talk a little bit about, with the report,
5 some of that work that we have done. You will be
6 seeing some of those things in the coming year as
7 she brings them forward.

8 And I would also just like to say that
9 this is the 24th year of PPAC. PPAC has been
10 going on for quite a long time. And I think that
11 over time, how the office and directors have used
12 PPAC has changed. And as Kathi said, she's
13 actually a very prolific user of PPAC, which we
14 really appreciate, it's been really lovely to be
15 able to work with the Agency so closely.

16 And we are aligned 100 percent on how to
17 utilize patents for the benefit of the nation.
18 And I cannot stress how impressed we at PPAC are
19 with the dedication of the staff of the USPTO. I
20 mean it is, you know, when you get behind the
21 curtain you don't understand how hard everyone
22 works to really help bring patents to impact and

1 really to benefit the nation. And so I just want
2 to say thank you to everyone at the USPTO for all
3 of your hard work, and we really appreciated
4 working with you guys this year.

5 Now we're going to talk a little bit
6 about the report. I know Kathi has to go back to
7 her office. I would like to ask for those online,
8 if you have questions, please feel free to put
9 them in the Chat. We have PPAC members as we're
10 going through the report that will answer some of
11 the easier ones. And we will be taking questions
12 at the end for anybody in the room or for those
13 online that need a little more discussion. So
14 next slide, please.

15 So our agenda today is we are going to
16 work through a little bit of each of the working
17 groups that we had this year for PPAC. I'm going
18 to do an introduction, then we're going to go
19 through a little bit about what is PPAC,
20 shockingly we still get questions about who we are
21 and what we do so we thought we would clarify that
22 for you. The rulemaking process and a lot of what

1 went into that this year, the general finances, a
2 discussion about artificial intelligence, working
3 with other government agencies, the FDA and USDA,
4 of course PTAB. And then bringing this to impact
5 and the impact on GDP. So next slide, please.

6 So as we've said before, the goal of
7 PPAC this year was to focus on how to utilize
8 patents for the benefit of the nation. And so we
9 really worked hard with Director Vidal to first
10 off link patents and inventions to increasing GDP,
11 right. I think first and foremost it is really
12 about jobs and money in the end, right. If you
13 can't invent something and bring it to market and
14 sell it, then these things aren't helpful, right.
15 So the more we can tighten that link the more we
16 can show that this is a path to wealth for
17 individuals and corporations, the better our
18 national economic bottom line.

19 We've also been focused on getting more
20 and different people into the invention ecosystem.
21 And so again, how can we get more of an invention
22 mindset in the United States, bring more people

1 into inventing all over the United States. This
2 is something that starts in early education, that
3 continues forward, we want this profession to be
4 not one that people accidentally end up in, but
5 one that people want to go into intentionally.
6 And so again, the USPTO has been working very hard
7 to bring that intentionality to a lot of what's
8 been going on.

9 The USPTO and PPAC wanted to make sure
10 that they're good financial stewards. First and
11 foremost as patent owners and patent participants,
12 your fees go to the running of this organization,
13 and we want to make sure that it's being done in a
14 very effective manner. And so again, we'll be
15 talking about the results of that and how that
16 works.

17 But, the USPTO does not deal with
18 patents in a vacuum. Other government agencies
19 also touch invention and innovation, and so more
20 collaboration with other government Agencies to
21 ensure that robust and reliable patents are issued
22 is required. We're going to talk a little bit

1 about the work that the USPTO has done with the
2 FDA and the USDA to help put forward that
3 collaboration and ensure that they have the best
4 data possible for robust and reliable patents.

5 And finally, we really want to make sure
6 that we increase stakeholder engagement. We want
7 to hear what the public has to say. And you can
8 see that through the request for comment, the
9 rulemaking process. This has been a banner year
10 for many of that, and so again, trying to ensure
11 that the public is heard, that we at PPAC have
12 heard you, and made sure that your voices are
13 represented as we go forward. Next slide, please.

14 So one of the things that we did at PPAC
15 was we talk a little bit about national
16 competitiveness, and you can see this in the
17 report. And national competitiveness is defined
18 as economic competitiveness, technological
19 competitiveness, and national security. And
20 really the process of invention and patents is
21 critical to each one of those components, right.
22 So as we link invention and patents to GDP, that

1 helps us with economic competitiveness, keeping
2 technological competitiveness, and ultimately even
3 national security, as more and more of our
4 invention is in the private sector and not just
5 the public sector or in the military.

6 I think a quote that was put in our
7 letter to the President that says today patents
8 are sources of both value and risk for companies
9 and both political and geopolitical tools for
10 nation states. This plurality of roles means that
11 patent stakeholders, including individual
12 inventors, companies, universities, federal
13 agencies, Congress, and the courts, are still
14 learning about these new uses of patents and how
15 they effect the system today and in the future.

16 Patents are working hard in multiple
17 dimensions. And I don't think that we as a nation
18 have completely grasped how that works and how
19 those things come together. And I think the USPTO
20 is doing a massive effort to try and educate and
21 understand those plurality of roles and what their
22 role is in bringing forward the value of the

1 right. And again, everyone here is working really
2 hard, and at PPAC we're very fortunate to be able
3 to work with them. Next slide, please.

4 And finally, again, as we prepare for
5 the future there's some really large issues that
6 are going to impact, you know, our economy overall
7 in the next coming years that relate to patents.
8 So we have artificial intelligence, I mean you
9 can't pick up a newspaper without hearing about
10 that. That's going to have an immense impact on
11 both invention, inventorship, tools, and
12 innovation, right. So we're going to look forward
13 to understanding those as that comes forward next
14 year.

15 Again, we have a period where the AIA
16 was implemented for over 10 years now, and so
17 again, beginning to look and see, did the
18 implementation of that meet the intentionality of
19 that. And again, some of that is related to data
20 which the USPTO has and will be sharing forward.
21 Collaborating with other agencies. As we said
22 before, the PTO needs to reach out as part of one

1 of many stakeholders in the government to have a
2 clear view of how patents can help the nation.
3 And so the more they can entertain and work with
4 other agencies, they can share data, the better
5 off we are as a nation. And so happy again to
6 report out on some of those activities.

7 And finally, working with the White
8 House, Congress, and the Department of Commerce,
9 the USPTO is working hard to make sure that
10 patents can help keep the nation safe, right.
11 That's first and foremost what we need to be
12 looking at is how does it help the nation, and
13 keeping that view of the nation in our minds first
14 and foremost at a system level is the most
15 important thing.

16 So again, just happy to share all these
17 thoughts. I do want to say one thing just for you
18 to keep in mind. One of the things we did in the
19 report was to try and actually prepare something
20 to talk a little bit about the rate of
21 technological change that's happening in our
22 nation. And I want to share a little vignette

1 with you.

2 It took 121 years for the USPTO to grant
3 the first million patents. In 2023, the USPTO
4 granted 340,000 patents, which means at that rate,
5 the next million patents will be granted in 35
6 months. That number continues to drop. I can't
7 stress enough how that volume of innovation is
8 affecting the agency. The rate of change is
9 enormous. It is only going to get faster as AI
10 becomes a tool that more and more people use. And
11 so as an Agency, we are all working very hard to
12 figure out how to handle that volume, how to
13 manage that volume, how to utilize it for the
14 benefit of the nation. And so again, I look
15 forward to all of us sharing our insights and now
16 we'll move forward. Next slide, please. I think
17 it's over to you, Olivia.

18 MS. TSAI: Thank you so much, Suzanne.
19 Hey, everyone, Olivia here again. I'm here to
20 give an overview of what is PPAC. Who are we and
21 what do we do.

22 Question, who are we? We're nine

1 private sector contributors from the IP community
2 and three USPTO labor organization leaders. We
3 serve three-year terms, those of us from the
4 private sector, that may be renewed once.

5 So what do we do? We are in a very
6 unique position to contribute, connect, and
7 enhance work. For example as Director Vidal
8 mentioned, she often engages us in pre- decisional
9 confidential discussions on potential changes and
10 guidance and other questions from the USPTO. We
11 also break into subcommittees and project groups
12 to support USPTO initiatives. And we offer
13 connections and context, bridging people outside
14 the USPTO with the USPTO in the form of guest
15 speakers and other two-way introductions. And all
16 of this in no more than 60 days per year. So that
17 is our limit. Next slide, please.

18 I'm also going to speak on the
19 rulemaking activities. You can go to the next
20 slide. With our review of the rulemaking
21 activities and other notices published in the
22 Federal Register by the USPTO. The rulemaking

1 timeline is generally one week, sorry, one year,
2 it's a one-year process. The first half of the
3 year it's generally for the NPRM phase, which is
4 the notice of proposed rulemaking phase. That is
5 when you guys see the notices in the Federal
6 Register, and then the second phase, which is
7 final rulemaking. So, all of that roughly equates
8 to one year.

9 And in addition to that, as Director
10 Vidal mentioned, there are other optional tools
11 that the USPTO uses such as the ANPRM, you know
12 that there was one that had a lot of written
13 comments this year. We also support the USPTO in
14 publishing their RFC, or Request for Comments, as
15 well. And Director Vidal and her team also do a
16 lot of live engagements with the public through
17 various listening sessions and other engagements.

18 The table there we can see is a summary
19 of various notices that were published, the volume
20 of notices, and the comments received by the USPTO
21 which they take into consideration to come up and
22 collaborate with the best-fit solution together.

1 So next slide, I will turn it over to my colleague
2 here, Charles, who will speak on finance. Thank
3 you very much.

4 MR. DUAN: Thanks, Olivia, that was a
5 fantastic presentation. And so I'll be talking
6 about the finance section of the PPAC Report. I'd
7 like to start just by thanking Jay Hoffman, the
8 CFO, and the rest of the finance team. They've
9 been incredibly helpful on helping us understand
10 what's going on. This is a large and complex
11 Agency and they've really done a really nice job
12 of breaking down what's been going on, helping us
13 to understand and be able to evaluate the
14 financial situation of the Agency.

15 So to begin with I think it's useful to
16 just give a little background on what's going on
17 in terms of finances. In fiscal year 2023 the
18 USPTO processed 515,000 new patent applications
19 and granted over 340,000 patents. That's with a
20 staff of over 8,000 patent examiners. That's a
21 very large operation for patent examination.
22 Patent examination accounts for the largest

1 portion of the Agency's costs, that was 2.9
2 billion in fiscal year 2023. If you'd go on to
3 the next slide, please.

4 For most agencies this money would come
5 from Congressional appropriations. But with the
6 USPTO it doesn't take any money from Congress,
7 instead it recovers all of the costs of its
8 operations from a fee funding model.
9 Appropriations are still required, Congress has to
10 provide authorization for the USPTO to use the
11 money that the Agency collects in fees. But
12 through the fees that the Agency collects for
13 examination and then through maintenance fees and
14 other fees that the Agency collects on granted
15 patents, those are what drive the ability of the
16 Agency to perform high quality examination and to
17 perform the services of granting patents for the
18 nation.

19 This isn't simply a cost for service
20 operation though. Because of the fact that we
21 want to make sure that there are opportunities for
22 small inventors to be able to enter the system

1 because we want to make sure that applicants are
2 able to have a fair chance at getting patents on
3 their inventions, the PTO offers a number of
4 different ways in which it encourages more people
5 to enter the system.

6 One of these are small micro entity
7 discounts. Small entities pay less fees for
8 examination. And also a lot of the costs are
9 essentially backloaded. The cost of applying for
10 a patent are generally lower, and then the cost of
11 examination are made up through maintenance fees
12 that are paid after the grant of the patent. And
13 so these are ways in which the Agency is still
14 recovering its costs but is able to accommodate
15 the interest in ensuring that there is access to
16 the patent system.

17 To sort of smooth things out, one of the
18 things that Jay has been really helpful in
19 explaining to us is that the PTO maintains an
20 operating reserve. This is essentially like a
21 savings account or a checking account that allows
22 the PTO to weather differences in patent

1 application filings to make sure that if filings
2 are very high and they need to spend a lot on
3 examination, they have the resources to do that.
4 They're able to smooth out those sorts of costs.
5 Could you move on to the next slide, please?

6 One of the biggest things that we talked
7 about in terms of finances were changes that had
8 happened recently and are potentially going to
9 affect the finances of the Agency going forward.
10 The two major changes that we contemplated were
11 the Unleashing America's Inventor Act, which was
12 enacted recently. This increased the discounts
13 for small and micro entities, which again is
14 important, and PPAC supports because of the fact
15 that it increases opportunities and access to the
16 patent system. But it also means that the overall
17 fee revenues forecasted for the Agency are going
18 to go down.

19 In addition, inflation and pay raises
20 and the costs of personnel are anticipated to go
21 up by about \$173 million per year. Based on the
22 current forecast that we received from the Finance

1 Office, we understand that the operating reserve
2 for the Patent Office will still remain above the
3 minimum required levels but will be on a declining
4 trend, and the Agency is taking a number of
5 measures that we think are very important to try
6 to address that oncoming challenge. If you could
7 move on to the next slide, please.

8 The biggest initiative of these is the
9 fee setting process. And so PPAC was very engaged
10 with that, we held a hearing in which we heard
11 testimony from a number of the members of the
12 public, we also received comments, we received
13 written comments from members of the public. I'd
14 like to emphasize that we are incredibly grateful
15 for that feedback. I read all of the comments, my
16 colleagues read all of those comments. We
17 prepared a report that summarized the views of the
18 public that was based on the comments that we
19 received. Those comments were incredibly
20 important for us in advising the Agency on how
21 they should move forward with the fee setting
22 process.

1 Again, we think that this fee setting
2 process is incredibly important in view of the
3 financial challenges and situations that we've
4 heard about, but we also want to make sure that
5 the views of the public are heard in that, and we
6 will continue to remain engaged in that process as
7 the PTO continues with its fee setting efforts.

8 Additionally, we've been told that the
9 Agency is taking on a number of other cost-saving
10 initiatives. It is relinquishing a number of the
11 building leases that are forecasted to save about
12 \$27 to \$50 million a year. It's also investing in
13 technology like artificial intelligence that will
14 again hopefully save costs and increase the
15 productivity and effectiveness of the Agency's
16 operations. Next slide, please.

17 I think our key takeaways based on our
18 review and our discussions with the Agency are
19 that the USPTO is in good financial shape, it
20 recognizes what the future situations are going to
21 look like and has a good handle on how it should
22 address those. Cost recovery for the PTO's

1 examination efforts and maintaining a strong
2 operating reserve continue to be critical.

3 As we detail in the report, we believe
4 that there are opportunities for the Agency to
5 work with Congress on greater flexibility and fee
6 setting and also addressing other concerns, in
7 particular concerns that the Agency has raised in
8 the past about unavailable collected patent fees
9 of about \$950 million. We provide recommendations
10 for the Agency working with Congress on how to do
11 that and how to generally continue working with
12 Congress to maintain the financial viability of
13 the Agency and to maintain the strength of its
14 operations.

15 All right. And I think next we have,
16 are you doing artificial intelligence, Lea?

17 MS. TSAI: No, that's Dan.

18 MR. DUAN: Dan, yeah, okay, Dan will be
19 presenting on artificial intelligence.

20 MR. BROWN: I hope everybody can hear
21 me. Sorry, I was talking to myself in the
22 introductions. Take a second to thank everybody.

1 This is my third year, and I'm rotating out of the
2 PPAC but I have to say it's been an amazing
3 experience. The quality of people, both in the
4 PPAC and in the office is truly amazing to me, and
5 I never expected such a fantastic life experience
6 of being able to contribute here.

7 I'm going to be speaking about AI. And
8 while AI tools are already being used in a limited
9 way, we have thoroughly looked through this and
10 the office is completely immersed in AI in terms
11 of how it can assist as a tool in searching and
12 working with the efficiency and the quality of the
13 searches.

14 I'm sort of hearing some background.
15 Anyway, AI has two principal areas, one is
16 inventorship, and the other is research. And
17 while inventorship is really statutory in terms of
18 who can be an inventor, AI is actually -- I hear
19 some background noise coming in.

20 MS. HARRISON: Dan, we can hear you just
21 fine, you just need to stay closer to the mic.

22 MR. BROWN: Did you hear that?

1 MS. HARRISON: No.

2 MR. BROWN: I'm basically going to take
3 my speakers down. In regards to inventorship, the
4 office is engaged in the statutory level of
5 inventorship where humans are inventors but being
6 challenged by the complexity of how AI is going to
7 be assisting inventorship, and that is going to be
8 an ongoing challenge. I think that the most
9 important aspect of AI and inventorship is the
10 fact that there's a presumption that AI is going
11 to give us a much higher quality and a much lower
12 cost and more efficacy in our searches. And I
13 think the PPAC would stress that we want to be
14 cautious here. We want to avoid the unintended
15 consequences of thinking that the AI is going to
16 save or even replace the examiner, which I just
17 cannot see that personally, and I don't believe
18 that that cost savings and that efficiency is
19 going to come out as fast as everybody would want
20 it to.

21 The reality is the critical thinking of
22 the examiner is extremely important in the

1 process, and within that we need to proceed with
2 caution and also proceed in a way I think where,
3 as AI is being brought in as a search tool, that
4 it is used in a way that is also a redundant
5 system, a good objective comparable analysis as to
6 what is actually happening at that point, and not
7 just assuming, as many people do with the new
8 technology of AI, that it's going to replace the
9 critical thinking of the human. To that extent,
10 next slide.

11 So I'm going to introduce the next
12 person, I'm not sure, I don't have that in front
13 of me right now. Henry's going to talk about
14 USPTO, the FDA, and the cooperation. Thank you.

15 MR. HADAD: Good morning everyone,
16 again. Before I start I did want to thank once
17 again Director Vidal and our colleagues at USPTO
18 for their partnership throughout the last year.
19 It's been incredibly informing to me, and I've
20 learned so much from you all, so I appreciate it.
21 I also wanted to thank my colleagues at PPAC, and
22 in particular our Chair and Co-Chair for their

1 leadership over the past year.

2 So turning to the issue of USPTO/FDA
3 communication. In July of 2021 there was an
4 Executive Order issued requiring that the FDA
5 communicate with USPTO to ensure that the patent
6 system on incentivizing innovation does not
7 unjustifiably delay generic and biosimilar
8 competition. And following that there were
9 similar requests made from Congress, particularly
10 focusing on the potential of conflicting
11 statements made to the FDA during review and
12 during USPTO examination.

13 Before we get into it, it's important to
14 note that there are very different roles of the
15 USPTO and FDA. FDA determines the safety and
16 effectiveness of new biopharmaceuticals. And
17 underlying this review is data generated during
18 pre-clinical and testing and clinical trials that
19 can take place over a decade. The drug discovery
20 and development process is extremely risky, with
21 many more failures than successes and can cost
22 billions of dollars. Which is why the biopharma

1 industry is the most R&D intensive industry. For
2 these reasons it's critical that the
3 biopharmaceutical industry, and particularly
4 products, have a meaningful period of exclusivity
5 to recoup these expenses, cover the successes and
6 many failures, and invest in the next generation
7 of cutting edge therapeutics to treat patients
8 with serious medical needs.

9 So a robust, reliable, and high-quality
10 patent right is critical in driving
11 biopharmaceutical innovation, and that's where
12 USPTO examination comes in. USPTO examination
13 determines whether the claims of a patent
14 application meet the statutory requirements for
15 patentability, e.g. primarily novelty,
16 non-obviousness, and the disclosure requirements
17 under Section 112. For these reasons FDA review
18 and PTO examination look at very different things.
19 And while there may be occasional overlap on
20 technical issues, it's more often not the case.

21 USPTO and FDA have worked diligently
22 this year and the preceding years, to explore with

1 each other and key stakeholders whether
2 information sharing can improve patent quality and
3 if so, what's the best way of doing that. And
4 since the 2021 Executive Order, I know that USPTO
5 and FDA have engaged in various cross-training
6 exercises, listening sessions, request for
7 comments, and creation of a website to enhance
8 accessibility to publicly available patent term
9 extension information.

10 PPAC supports USPTO's ongoing efforts to
11 review whether information sharing with FDA would
12 improve patent quality. So long as this
13 information sharing does not publicly disclose
14 confidential or trade secret information, provides
15 meaningful improvements in patent quality, and in
16 no way impedes USPTO examination or FDA review.

17 While PPAC is supported by these efforts
18 -- we can go to the next slide now -- it is
19 important to note that PPAC has not been presented
20 with any data that suggests that potential
21 inconsistency of representations to each agency is
22 a practice warranting significant changes in

1 either FDA review or USPTO examination.

2 The Hatch Waxman Act has been in place
3 for nearly 40 years, and over that time thousands
4 of patent cases have been litigated. Despite
5 this, only two cases have been cited as examples
6 of a potential problem, neither involving
7 innovator biopharmaceutical companies, and in both
8 cases the system worked and the patents were found
9 unenforceable.

10 This is illustrative of a larger trend
11 where at times unsupported statements around IP
12 practices are often taken as reality or when facts
13 are cited they are either inaccurate or
14 misleading. This could lead to significant and
15 inefficient use of Agency time reviewing
16 off-target policy proposals or even worse, lead to
17 the adoption of ill-informed policies.

18 To be clear, PPAC believes any patent
19 reform proposals should be clearly supported by
20 facts and believes that USPTO is uniquely
21 positioned to provide this data and champion
22 evidence-based policy reform. In 2022 Senator Tom

1 Tillis noted in some communications that several
2 of the main sources driving the narrative around
3 biopharmaceutical patent practices do not appear
4 to meet the fundamental criteria of being based on
5 accurate facts and being from reliable, unbiased
6 sources. And for that reason he requested that
7 USPTO and FDA conduct an independent study
8 assessing data from several data sources about
9 patenting practices in this industry.

10 PPAC supports USPTO and FDA efforts to
11 complete this report as a generation of relevant
12 patent and exclusivity data and accurate market
13 exclusivity data will assist policymakers in
14 making informed decisions on patent related
15 policies. This is really important.

16 PTO has the independence, the data, and
17 the expertise, and should be utilizing it to test
18 these narratives. Equally important, USPTO also
19 has an important role as a champion of the IP
20 system and driving innovation, and makes sure that
21 narratives and rhetoric are tested against the
22 facts and then any policy changes are focused on

1 ensuring a more robust and reliable patent right
2 to drive innovation, economic growth, and global
3 competitiveness.

4 And with that I will stop and turn it
5 over to Heidi.

6 MS. NEBEL: Thank you. I would like to
7 thank our PPAC Chair for this amazing year that
8 we've had and for all that you've done to elevate
9 the role of PPAC within the Patent Office and
10 within the country.

11 First of all I would like to talk a
12 little bit of background about plants. It is a
13 well-accepted statistic that by 2050 the global
14 population is expected to reach 9.7 billion, which
15 will require a 70 percent increase in agricultural
16 productivity. Combine that with climate change
17 and dwindling land available for crop production,
18 90 percent of the required increase to feed this
19 increased population will need to come from
20 technological advances in farming practices. Food
21 security is national security.

22 Several high-profile prosecutions in the

1 U.S. access or economic espionage by foreign
2 nationals, including China, of plant breeding
3 materials and technologies have raised awareness.
4 The FBI Director, Christopher Ray, said American
5 agriculture is one of the softest targets for IP
6 theft. Whether through access to privileged
7 company research, transfer of information out of
8 university or government research facilities, or
9 by the simple act of digging up plants in a field.
10 Next slide, please.

11 The United States has the strongest
12 system for plant protection in the world. We have
13 three different regimes for protection of plant
14 developments. We have plant patents, we have
15 utility patents, and we have PVPs, Plant Variety
16 Protection Certificates, which are administered by
17 the United States Department of Agriculture.
18 Strong IP protection gives Americans weapons to
19 fight germ plasma theft and spurs investments in
20 plant breeding.

21 In 1985 the case of *ex parte* Hibberd
22 endorsed the protection of utility patents for

1 plant varieties. And so with that we had an
2 opportunity to see something that was heretofore
3 unpatentable, now becomes patentable. And what
4 changes did we see in the agricultural economy?
5 According to conservative estimates, the
6 introduction of patent protection increased the
7 total value of U.S. agricultural land in 2002 by
8 7.5 percent, roughly \$80 million. \$117 billion in
9 2020 dollars. This increase occurred despite the
10 presence of plant patents and plant variety
11 protection certificates that were available,
12 indicating the perceived value of utility patents.
13 Next slide, please.

14 So with all this background we look at
15 the July 2021 Executive Order from President Biden
16 encouraging collaboration among agencies. So the
17 USPTO and the USFDA are now collaborating to
18 increase, and USPTO created an interagency working
19 group on competition and intellectual property in
20 seeds and other agricultural input. This group
21 has continued to work together and much has been
22 done to secure strong IP rights while also

1 promoting healthy competition in the agricultural
2 sector. Increased transparency between these two
3 agencies should be continued to secure both rights
4 and to maintain the vitality of both rights.

5 The working group has included a website
6 that has been introduced to the USFDA to identify
7 patent varieties that are the subject of patents,
8 to increase accessibility of seeds that have come
9 off patent, and outreach to farmers to provide
10 education and the role of IP, including
11 cooperation between the USFDA PVP system and the
12 USPTO system for prior art.

13 It is important to remember however,
14 that these are two separate systems with separate
15 rights that are granted and separate exemptions.
16 Attention remains to maintain the advantage of
17 utility patents in our national security and our
18 global economy and to avoid compilation of patents
19 and PVPs to one entity. We must proceed with
20 caution with this continuing cooperation while it
21 does have advantages and the patent office has
22 aggressively pursued this cooperation.

1 With that I will turn it over to Steve.

2 MR. CALTRIDER: Thank you. We've heard
3 from the Director as well as Suzanne in her
4 comments today about the importance of the strong
5 innovation economy in a role of the patent system.
6 And I wanted to start my comments off with just a
7 reminder of the constitutional foundation for
8 that. Of course the U.S. Constitution Article I,
9 Section 8 provides for the U.S. patent system to
10 promote innovation. And that system is absolutely
11 essential to drive jobs and prosperity. And to do
12 so though, you need to have confidence. The
13 patent right has to be reliable, has to be robust,
14 and that's one of the reasons the Patent Office,
15 as well as the PPAC, is focused so much on that
16 today.

17 I also want to comment that the staff,
18 and this is echoing comments of others, the staff
19 in the PTAB, the staff at the Office of
20 Examination Corp have done just simply an
21 outstanding job. I don't think there's a person
22 that I've encountered during my entire tenure of

1 PPAC, but certainly this year, that is not focused
2 in understanding the importance of the patent
3 system and is not truly dedicated and committed to
4 the role of the patent system to drive a strong
5 innovation to the economy. People get it. We are
6 working very, very hard to make improvements, and
7 I will cover today a number of improvements that
8 are ongoing, not only in the advanced roles that
9 promote rule making, but in other steps that the
10 PTAB and the examination corp have taken to just
11 do that to improve the system. Next slide,
12 please.

13 Of course the Patent Trial and Appeal
14 Board -- next slide, please -- started in
15 September 2011, it was established by the AIA.
16 The proceedings are intended to establish a more
17 efficient and streamlined patent system that will
18 improve the quality and limits unnecessary
19 counterproductive litigation costs. It also was
20 recognized that it could be a vehicle for
21 harassment. The Patent Office has been trying to
22 balance those two considerations. How do you

1 provide quick and cost effective alternatives to
2 litigation, at the same time recognizing that
3 there could be abuse in the system and harassment
4 of patent owners, and how do you mitigate that.
5 So those have been the dual priorities of the AIA
6 from day one.

7 It's been in place about 20 years now,
8 so we do have data that continue to inform how
9 things are going. And I think it's important to
10 look at those data and recognize where there's
11 opportunity to improve and where things are going
12 well, and we want to reinforce those actions.

13 The data I'm sharing today are
14 predominately available on the Data Digitalization
15 Center on the Website. And so I'd encourage you
16 to go there. There's obviously a more robust
17 collection of data that you should take a look at.
18 Next slide, please.

19 Let's start with IPR remains the most
20 prevalent proceedings on the AIA. 98 percent of
21 the petitions go to AIA, or to IPR, sorry.
22 There's probably some considerations on that that

1 aren't surprising. You can file an IPR at any
2 time, and oftentimes we'll talk about, in a bit,
3 they're triggered by litigation. So those two
4 considerations probably have driven those. But I
5 can say, just because I was involved in some of
6 the discussions leading to the AIA as well, this
7 is unexpected. People didn't expect to see 98
8 percent IPRs and a relatively low percentage, 2
9 percent, of PGRs. And so this is something that
10 we need to learn from, we need to understand, we
11 need to decide, is this the balance that we
12 expected to have, or is this something that should
13 be addressed more fulsomely.

14 One of the most prevalent pieces of
15 feedback that the PPAC has received over the
16 course of this year, even during the fee setting
17 hearings and in past years, has been how
18 disruptive IPRs can be to the expectation of
19 investors and inventors. You can challenge them
20 at any time, that means they can occur at any time
21 and often times it's after the investment's been
22 made and after some of the market has been

1 developed, and that puts a great deal of strain in
2 the system. And again, that's one of the reasons
3 this needs to be studied further.

4 The other aspect notable is 80 percent
5 of IPR proceedings have parallel litigation in
6 Federal District Court. It's worth noting that 20
7 or 30 percent of the Federal District Court
8 proceedings don't have a parallel proceeding, so
9 it's clear there's still a balance. But 80
10 percent really goes to that question on is it more
11 cost effective or is it just really providing a
12 second vehicle to challenge a patent in which case
13 costs are increased and the level of complexity
14 increased. Again, it's a question that really
15 needs to be considered further.

16 The office in this regard, however, has
17 done a tremendous job in studying this issue. The
18 Director has issued guidance on this to try to
19 clarify when it's appropriate to have Federal
20 proceedings and when not. The PTAB has issued a
21 number of precedential opinions on this. So it is
22 something that is an active body of work not only

1 this year but in the years going forward because
2 it's obviously a key consideration on whether or
3 not the objectives of the AIA are being achieved
4 in the system.

5 The PPAC applauds the USPTO for staying
6 on top of this and continues to study this issue,
7 and encourages the USPTO to continue to do so in
8 the future years. Next slide, please.

9 Institution rates have been relatively
10 flat. Again, I think this speaks volumes on the
11 work of the PTAB to provide clarity on the
12 criteria for institution and when things will be
13 denied and when things won't be denied. There's
14 been a number of precedential opinions and
15 guidance from the office in this regard. It is a
16 trend to continue to watch, it's something that
17 even though it remains flat year to year,
18 generally speaking, it is a trend that should be
19 watched, particularly the last four years have
20 increased slightly, and so just watching that to
21 continue to understand and dig into the data in a
22 little more detail on why that may be the case.

1 Next slide, please.

2 Outcomes by patent. 42 percent of the
3 patents with AIA challenge in the year 2023
4 resulted in a final written decision, which is the
5 FWAD on the slide. 26 percent of patent
6 challenges resulted in denial of institution, 27
7 percent settled before reaching a final written
8 decision, 5 percent were terminated or dismissed
9 for other reasons. When looking at the final
10 written decisions by patent, of the 42 percent
11 that reached a final written decision, 67 percent
12 of those resulted in all challenged claims being
13 found unpatentable. Approximately 17 percent
14 resulted in mixed results, that is some claims
15 patentable and some claims unpatentable, and about
16 16 percent resulted in all claims being upheld.

17 Again, the most consistent feedback we
18 heard from the public and stakeholders is the
19 importance of reliable and durable patent rights.
20 The PPAC applauds the USPTO for keeping the
21 reliability and the durability of a patent right a
22 top priority. It certainly properly is given the

1 role of patents in the ecosystem.

2 One item since the AIA now is 20 years
3 in its making is the opportunity to use each
4 decision and each outcome as an opportunity to
5 learn and understand. In past PPAC years we've
6 referred to this as closing the group or closing
7 the gap, and all sorts of different nomenclatures.
8 But it really is just continuous learning that the
9 opportunity presents itself with the PTAB issuing
10 a decision in terms of what happened. The PTAB,
11 the office has called this their Outcome Study. I
12 encourage the office to continue their Outcome
13 Study as it provides very, very insightful data
14 from which applicants, as well as the office, can
15 learn and improve. Next slide, please.

16 In this Outcome Study, and this was the
17 calendar year 2021 sampling the data, successful
18 challenges having at least one claim found invalid
19 in a final written decision were sampled to
20 generate these data. 93 percent of the challenges
21 find the unpatentability of at least one
22 independent claim were based on prior art not

1 cited in prosecutions. 74 percent it was the only
2 new prior art, 19 percent were based on a mixture
3 of previously cited art and art, and 7 percent of
4 the challenge presented finding one independent
5 claim unpatentable were based on prior art cited
6 in the examination of the patent.

7 Notably in the 7 percent of challenges
8 that found at least one independent claim
9 unpatentable, 82 percent of those had more than
10 100 references cited by the applicant and
11 information disclosure statement. There's
12 certainly not enough data to statistically
13 establish this, but that leads to at least an
14 inference from the data that over citation can be
15 counterproductive to the robustness and
16 reliability of the patent right. Certainly the
17 PPAC encourages the office to continue to study
18 these and understand whether changes in ideas,
19 practice, need to be considered in view of some of
20 these data. Next slide, please.

21 So what are the takeaways? First and
22 foremost, the Outcome Studies from the office

1 should continue. The PPAC thinks it's
2 extraordinarily invaluable data, and continuing to
3 build this data set will further inform not only
4 actions by the office, actions by applications,
5 but also actions by Congress to improve the
6 system.

7 Percent of final written decisions
8 framed on patentability over at least one
9 independent claim based only on prior art not
10 cited in prosecution. That's a lesson to
11 applicants. The USPTO doesn't bear the sole
12 responsibility for quality. Applicants bear a
13 tremendous responsibility for quality, and
14 obviously finding the right prior art, the office
15 has a role in doing that, applicants have a role
16 in doing that, it's very, very important. So the
17 applicants need to take on these data and
18 understand what the implications are if they file
19 patents blindly without searching the prior art,
20 the likelihood of a different outcome than you
21 expect might be there. If you search the prior
22 art and work with the office to make sure those

1 prior arts are appropriately before the examiner,
2 there's a pretty good chance the office is going
3 to get it right according to these data.

4 The PPAC encourages the office to
5 continue to study and engage the applicant
6 community to understand the implications of
7 search, understand the barriers that perhaps limit
8 the applicant's willingness to engage the office
9 productively, that is for example, inequitable
10 conduct and whether or not reform of those issues
11 would be more beneficial to having a robust and
12 reliable patent right.

13 Finally, 80 percent of the IPR
14 proceedings having parallel litigation in Federal
15 District Court. This is a concern because it adds
16 on top of costs, adds on top of complexity, it's
17 something that needs to be continued to be
18 studied. The efforts by the office to mitigate
19 the instances, the duplicates in litigation or
20 duplicate proceedings is extraordinary and should
21 continue. But it's certainly an issue that needs
22 to be, warrants further study by the PPAC as well

1 as the office.

2 Thank you.

3 MS. DARDEN: Good morning again. Before
4 I begin I just want to thank Director Vidal and
5 the colleagues at the PTO for all the hard work
6 and support that you've given PPAC over the year.
7 We've done a lot, so thank you for giving of your
8 time to us.

9 I'd like to thank our outgoing
10 leadership for all your direction and guidance
11 over this year. You pushed us, we got a lot of
12 work done, and I think we've done some great work
13 on behalf of the stakeholders.

14 And to my colleagues on the PPAC, thank
15 you again. Steve, we'll miss you. Dan and Judge
16 Braden, as you move off to bigger and better
17 things in life, but know that we will continue the
18 hard work and may be calling on you in the future
19 for your continued guidance.

20 I have the privilege of wrapping up the
21 content of our report, and we're going to talk a
22 little bit about what Director Vidal has already

1 keyed up for you this morning in her remarks, and
2 that's reaching more inventors.

3 I'd like to tell you a little bit about
4 why that is so important. If we quadruple the
5 number of inventors we could increase the overall
6 level of USGDP by up to 4.4 percent. For some,
7 for a reference as to what that means, that could
8 mean adding up to at least a trillion dollars to
9 GDP annually.

10 There are also reports that show that by
11 increasing the number and the diversity of
12 innovators that we bring into the innovation
13 ecosystem, companies with above-average diversity
14 in their innovation team produce a greater
15 proportion of revenue from innovation, 45 percent
16 of the total, than companies who did not have
17 diverse or inclusive innovation teams.

18 So when we think about using patents to
19 sustain GDP, support economic development,
20 incentivize innovation, inclusive innovation is a
21 big part of that. So key takeaways from the work
22 that has been done this year are that the USPTO

1 has been successful in increasing national
2 competitiveness through both increasing invention
3 activity and making patent protection available to
4 more inventors around the U.S.

5 Director Vidal talked about some of the
6 initiatives that have been taken place over the
7 past year. The women entrepreneurs initiative,
8 she talked about the pro bono program, the
9 effectiveness of the K through 12 program. One of
10 the things that we want to continue to do with our
11 educational outreach is to move beyond K to 12 and
12 start looking at some of the community colleges,
13 vocational, educational institutions so that we
14 again start to grow and continue to grow that pool
15 of unrepresented inventors.

16 Another takeaway. The USPTO has
17 successfully increased its outreach, education,
18 and pro bono efforts to more effectively reach
19 students, practitioners, and communities in
20 under-represented geographies and demographics.

21 A highlight of this year is the Patent
22 Pro Bono Program and the impact it's had.

1 Particularly with a 45 percent year over year
2 increase in applicants in 2/1 of 2023. We expect
3 to see that program continue to grow and serve
4 under-represented inventors in the future.

5 The USPTO has also been successful in
6 partnering with both private and non-profit
7 sectors to provide more education, awareness,
8 tools, and assistance, to students, practitioners,
9 entrepreneurs, and unrepresented geographies and
10 demographics. And one of the programs that has
11 been a highlight of this year is the Pro Se
12 Assistance Program. So the office is engaged in
13 quite a few activities to help grow that pool of
14 under-represented inventors, and we expect to
15 continue that work in the future. Thank you.

16 MS. HARRISON: Well that wraps up so far
17 our presentation on the report. We want to open
18 it up for questions for those of you that have
19 anything you would like to say in the room or
20 online. If you're online could you please send in
21 your questions via the Chat function. I'm looking
22 over here in the room to see if anybody has any

1 questions or we were so incredibly explicit that
2 it was perfectly understandable?

3 Give everybody a second, they're going
4 to type quickly. While we do that I also just
5 want to say one thing for our departing members,
6 Dan and Steve and Judge Braden. You really and
7 truly will be missed, and it's really just been a
8 pleasure to work with you, and we will continue to
9 work with you in the future, you can't get away
10 once you've participated on PPAC.

11 Any questions coming through? All
12 right. Well I guess that we were so incredibly
13 clear that we don't need to worry about it. But
14 if you do have questions in the future, you can go
15 ahead and email PPAC at USPTO.gov, we will answer
16 those questions as they come in.

17 And again we want to thank you for
18 taking the time with us today to listen to the
19 report. And again, if you have any questions,
20 please go ahead and send them to us. We want to
21 thank the office for their participation in this
22 year, Heidi and I have been very happy to work

1 with all of you. And again to all our colleagues
2 at PPAC, it's been a fun year.

3 And then we want to hand the torch over
4 to Loletta and Charles to take up the reins for
5 next year. So stay tuned and we'll be seeing you
6 soon. Thank you so much.

7

8 (Whereupon, at 11:29 a.m., the
9 PROCEEDINGS were adjourned.)

10

* * * * *

11

12

13

14

15

16

17

18

19

20

21

22

1 CERTIFICATE OF NOTARY PUBLIC

2 COMMONWEALTH OF VIRGINIA

3 I, Thomas Watson, notary public in and
4 for the Commonwealth of Virginia, do hereby certify
5 that the forgoing PROCEEDING was duly recorded and
6 thereafter reduced to print under my direction;
7 that the witnesses were sworn to tell the truth
8 under penalty of perjury; that said transcript is a
9 true record of the testimony given by witnesses;
10 that I am neither counsel for, related to, nor
11 employed by any of the parties to the action in
12 which this proceeding was called; and, furthermore,
13 that I am not a relative or employee of any
14 attorney or counsel employed by the parties hereto,
15 nor financially or otherwise interested in the
16 outcome of this action.

17

18 (Signature and Seal on File)

19 Notary Public, in and for the Commonwealth of
20 Virginia

21 My Commission Expires: September 30, 2025

22 Notary Public Number 256314

